Category: Federal Forum Posters
Purpose: According to the Centers for Disease Control and Prevention, type 2 diabetes mellitus (DM) is the seventh most common cause of death in the United States. Management of blood glucose levels and hemoglobin A1c is essential for preventing macrovascular and microvascular
complications. Despite guidelines currently available regarding management of DM, data on the addition of GLP-1 agonists or empagliflozin is warranted. The goal of this project is to determine the efficacy and tolerability of empagliflozin or GLP-1 agonists when added to current DM therapy in veterans with type 2 diabetes mellitus, at the James J. Peters Veterans Affairs Medical Center.
Methods: Utilizing electronic patient records, a retrospective chart review was conducted within a veteran population to identify those who were prescribed empagliflozin or a GLP-1 agonist, in addition to their previous DM regimen. Patients who were eighteen to eighty-five years old with type 2 DM were included in the study. Patients were excluded if they had contraindications to therapy for GLP-1 agonists or empagliflozin or did not have required laboratory values. Data collection included baseline patient demographics, past medical history, adherence, prescriber (MD/PharmD), frequency of follow-up, diabetes medications (including daily doses and titrations), hemoglobin A1c, weight, blood pressure, hemoglobin, serum creatinine, lipid values, and documented side effects. The primary endpoint was to determine the effect of the initiation of GLP-1 agonists or empagliflozin on hemoglobin A1c reduction after 6 months, when added to basal/bolus insulin or oral therapy. The secondary endpoint was to examine the tolerability of the respective add-on agents based on reported adverse drug events.
Results: Not applicable
Conclusion: Not applicable
Kirsten McGorty– Pharmacist, James J. Peters VA Medical Center, Yonkers, NY